BioLineRx Ltd. (BLRX)
Oxford Ledge is still expanding full research coverage of BLRX. A live quote, fundamentals, and analysis are available in the app; the SEC-sourced material below is what we currently have indexed here.
Business summary
BioLineRx is an Israeli biopharmaceutical company developing oncology and rare disease therapies, including the approved drug APHEXDA and the novel candidate GLIX1.
SEC filings
- 6-K Interim report (foreign private issuer) 2026-07-08
- 6-K Interim report (foreign private issuer) 2026-05-27
- 6-K Interim report (foreign private issuer) 2026-05-22
- 6-K Interim report (foreign private issuer) 2026-05-19
- 6-K Interim report (foreign private issuer) 2026-04-28
Source: SEC EDGAR.
- Open BLRX in the Oxford Ledge terminal — live quote, chart, and analysis in the app.
- Browse the covered-stock index
- Learn to analyze stocks yourself
The material above is drawn from public SEC EDGAR filings and is provided for educational purposes, not as investment advice. Live pricing and fundamentals are available in the terminal.